FDA Briefing Documents Question Safety, Efficacy of Sarepta’s DMD Gene Therapy
Sarepta’s biomarker-based data “do not provide unambiguous evidence” of the therapy’s likely benefit for Duchenne muscular dystrophy patients, according to the regulatory agency.
FDA Briefing Documents Question Safety, Efficacy of Sarepta’s DMD Gene Therapy Read More »
